医学
心脏病学
肝素
内科学
冠状动脉疾病
心肌梗塞
抗凝剂
冠心病
血流
梅德林
冠状动脉血流储备
血流动力学
临床试验
冠状动脉循环
流量(数学)
冠心病
急性冠脉综合征
作者
Menglong Wang,Jing Chen
标识
DOI:10.1093/eurheartj/ehaf850
摘要
This commentary refers to ‘Heparin administration at first medical contact vs immediately before primary percutaneous coronary intervention: the HELP-PCI trial’, by J. Chen et al., https://doi.org/10.1093/eurheartj/ehaf481 and the discussion piece ‘Pre-hospital vs Cath-Lab heparin in STEMI: a reappraisal based on the HELP-PCI trial findings’, by B. Zhang, https://doi.org/10.1093/eurheartj/ehaf849. We thank Dr Zhang for their interest in our trial and their thoughtful comments regarding the HELP-PCI study.1 We appreciate the opportunity to address these points and clarify our methodology and interpretations. Firstly, we acknowledge that our trial was open-label, which may introduce potential performance bias. However, the primary endpoint [TIMI flow grade 3 (TFG-3) in the infarct-related artery (IRA)] was assessed by an independent core laboratory blinded to treatment allocation, thereby minimizing assessment bias. More importantly, key procedural strategies, including thrombus aspiration, stent implantation, and the use of glycoprotein IIb/IIIa inhibitors, were comparable between the two groups. This indicates that interventional cardiologists did not adopt a more aggressive thrombus management approach in the pre-treatment group, mitigating concerns about performance bias.
科研通智能强力驱动
Strongly Powered by AbleSci AI